Similar articles

• Vanzacaftor, tezacaftor, and deutivacaftor (Alyftrek) for cystic fibrosis.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2025 Mar 17;67(1724):41-43. doi: 10.58347/tml.2025.1724a. Med Lett Drugs Ther. 2025. PMID: 40053374 No abstract available.
• Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.

  Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Uluer AZ, et al. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Lancet Respir Med. 2023. PMID: 36842446 Clinical Trial.
• The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.

  Becq F, Mirval S, Carrez T, Lévêque M, Billet A, Coraux C, Sage E, Cantereau A. Becq F, et al. Eur Respir J. 2022 Feb 24;59(2):2100671. doi: 10.1183/13993003.00671-2021. Print 2022 Feb. Eur Respir J. 2022. PMID: 34266939
• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).

  Southern KW, Murphy J, Sinha IP, Nevitt SJ. Southern KW, et al. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2023 Nov 20;11:CD010966. doi: 10.1002/14651858.CD010966.pub4. PMID: 33331662 Free PMC article. Updated.
• Elexacaftor/Ivacaftor/Tezacaftor: First Approval.

  Hoy SM. Hoy SM. Drugs. 2019 Dec;79(18):2001-2007. doi: 10.1007/s40265-019-01233-7. Drugs. 2019. PMID: 31784874 Review.